PD-1 And PD-L1 Inhibitors Market to Record a CAGR of 19.31%, Increasing Prevalence of Cancer to Boost Market Growth

NEW YORK, Sept. 23, 2022 /PRNewswire/ — The “PD-1 And PD-L1 Inhibitors Market by Application (solid tumors and blood-related tumors) and Geography (North America, Europe, Asiaand Rest of World (ROW)) – Forecast and Analysis 2022-2026″ report has been added to Technavio’s offering. The potential growth difference for the PD-1 and PD-l1 inhibitors market size between 2021 and 2026 is USD 49.34 billion. To get the exact CAGR and the YOY growth rate, Request a FREE PDF Sample Report

Technavio has announced its latest market research report titled Global PD-1 and PD-L1 Inhibitors Market 2022-2026

Regional Analysis

North America will account for 51% of the market’s growth during the forecast period. This growth is attributed to factors such as the increasing prevalence of various solid tumors and blood-related tumors in the region and the sales of approved therapeutics. However, market growth in this region will be slower than the growth of the market in other regions. The US and Canada are the key countries for the PD-1 and PD-L1 inhibitors market in North America.

Key Market Dynamics

  • Market Driver: The increasing prevalence of cancer is driving the growth of the market. Various novel therapies have been approved in recent years. There is a gap between the demand and supply of these therapies, which has led to a huge unmet need. This has given vendors an opportunity to conduct studies on drugs such as PD-1 and PD-L1 inhibitors. The increasing approvals of these inhibitors are expected to increase their demand, which will drive the growth of the global PD-1 and PD-L1 inhibitor market.

  • Market Challenge: The high cost of available PD-1 and PD-L1 inhibitors will challenge the PD-1 and PD-L1 inhibitor market during the forecast period. The cost of cancer treatment is high, mainly due to laboratory tests, hospitalization, and the administration of novel PD-1 and PD-L1 inhibitor therapeutics. The treatment cost of these therapeutics depends on the stage of cancer. The high cost is leading to a rise in the preference for alternative treatment options such as surgeries, which is hindering the growth of the focused market.

Technavio has identified key trends, drivers, and challenges in the PD-1 and PD-L1 inhibitors market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report

Market Segmentation

By application, the blood-related tumor segment will be the largest contributor to market growth during the forecast period. The growth of this segment is attributed to factors such as the strong prevalence of leukemia and various types of lymphomas globally.

View our FREE PDF sample report for additional insights into the contribution of all the segments and regional opportunities in the report.

Some Companies Mentioned

  • Akeso Inc.

  • Alphamab Oncology

  • Amgen Inc.

  • AstraZeneca Plc

  • BeiGene Ltd.

  • Bristol Myers Squibb Co.

  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

  • Eli Lilly and Co.

  • F. Hoffmann La Roche Ltd.

  • Gilead Sciences Inc.

  • GlaxoSmithKline Plc

  • Innovent Biologics Inc.

  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.

  • Merck and Co. Inc.

  • Merck KGaA

  • Novartis AG

  • Pfizer Inc.

  • Regeneron Pharmaceuticals Inc.

  • Sanofi

  • Shanghai Jhunsi Biosciences Ltd.

Want your report customized? Speak to an analyst and personalize your report according to your needs

Related Reports

Point of Care Diagnostics Market by Product, End-user, and Geography – Forecast and Analysis 2022-2026: The point of care diagnostics market share is expected to increase by USD 13.09 billion from 2021 to 2026.

Pharmacogenomics Market by End-user and Geography – Forecast and Analysis 2022-2026: The pharmacogenomics market share is expected to increase by USD 2.50 billion from 2021 to 2026.

PD-1 And PD-L1 Inhibitors Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 19.31%

Market growth 2022-2026

USD 49.34 billion

Market structure

Fragmented

YoY growth (%)

18.6

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 51%

Key consumer countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get customized segments.

Browse Health Care Market Reports

Key Topics Covered

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Application

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/

Global PD-1 and PD-L1 Inhibitors Market 2022-2026

Global PD-1 and PD-L1 Inhibitors Market 2022-2026

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/pd-1-and-pd-l1-inhibitors-market-to-record-a-cagr-of-19-31-increasing -prevalence-of-cancer-to-boost-market-growth—-technavio-301630698.html

SOURCE Technavio

Leave a Comment